PFE Sep 2024 25.000 call
| Previous close | 4.7000 |
| Open | 5.0500 |
| Bid | 4.3500 |
| Ask | 5.1000 |
| Strike | 25.00 |
| Expiry date | 2024-09-20 |
| Day's range | 4.6800 - 5.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.36k |
- Yahoo Finance Video
Weight loss drug pricing under fire with pills on the horizon
Senior health reporter Anjalee Khemlani joins Brad Smith and Madison Mills on Catalysts to take a look at pharmaceutical stocks like Novartis (NVS) and Novo Nordisk (NVO) as weight loss drug makers are set to meet with lawmakers like Senator Bernie Sanders to discuss pricing. Khemlani provides insight into the weight loss drug market and pricing in the US compared to other countries around the world. She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Naomi Buchanan.
Insider MonkeyPfizer Inc. (PFE): Among the Best Stocks to Buy for Passive Income
We recently compiled a list of the 7 Best Stocks to Buy for Passive Income. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other good stocks to buy for passive income. With rising costs in today’s world, people are constantly searching for ways to earn additional […]
ZacksNovartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
